Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (888) 282-7099 Click to print page  Print

Browse Trials


Find Breast Cancer Clinical Trials That Are Right For You

The clinical trials listed below are open in the U.S. for people with DCIS (stage 0), stage 1, stage 2, stage 3, or stage 4 (metastatic)
breast cancer. Clinical trials are available for people who are newly diagnosed with breast cancer, currently in treatment, experiencing
breast cancer recurrence, living with metastatic disease, as well as breast cancer survivors who have completed treatment.

Use the search box and filters to find a trial that’s right for you.


Currently viewing trials
(Last updated: March 18, 2023)

Zip Code:
 

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 
 
Close
Treatment

Brain Mets

BRCA1/2 (inherited)

Chemotherapy

Hormone Therapy

Leptomeningeal Disease

Radiation Oncology

Surgery

Surgery: Reconstruction

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Tumor Mutations

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment

Non-Treatment

Activities

Complementary and Alternative Medicine

Decision Support

Diagnosing Breast Cancer

Genetics/Family History

Having Children

Lymphedema

Managing Side Effects

No Travel Required

Predicting Response to Treatment

Preventing Breast Cancer

Preventing Recurrence

Screening

Support/Education

Surveys/Interviews/Registries

Close

AKT

ALK

AR

BARD1

BRCA1/2 (tumor)

BRIP1

CD205

CD70

CHEK2 or CHEK1

ESR1

FGFR

HER2/ERBB2

HLA

MET or C-Met

NTRK

PALB2

PIK3CA or PI3K

PTEN

RAD51

RAF (including BRAF)

RAS (KRAS or NRAS)

RB

ROS1

TP53

Click here to view online studies and trials that do not require site visits

1

NEAREST SITE: 3 miles
Curebase
San Francisco,CA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT04510129

Collecting Tumor Samples to Develop a Test to Predict Response to Treatment

Predicting Immunotherapy Efficacy From Analysis of Pre-treatment Tumor Biopsies Scientific Title

Purpose
To collect tumor samples that will be used to develop OncoPrism™, a test that helps providers predict response to immunotherapy.
Who is this for?
People with stage I, stage II, stage III, or stage IV (metastatic) triple negative (ER-, PR-, HER2-) breast cancer who have received or are planning to receive treatment with a PD-1/PD-L1 inhibitor. You must have received a biopsy before beginning treatment with a PD-1/PD-L1 inhibitor.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tumor samples</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">OncoPrism™ is a test that helps providers predict response to immunotherapy.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04510129' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://cofactorgenomics.com/technology/' target='_blank'>Cofactor Genomics: OncoPrism™ Test</a> </li></ul>
See more
2

NEAREST SITE: 3 miles
University of California San Francisco
San Francisco,CA

VISITS: Online surveys

PHASE: NA

NCT ID: NCT02620852

WISDOM Study: Women Informed to Screen Depending on Measures of Risk

Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer Scientific Title

Purpose
To learn if risk-based breast screening is as safe and effective as annual mammogram screening for reducing risk and detecting breast cancer.
Who is this for?
Women between the ages of 40 and 70 who have never been diagnosed with breast cancer or ductal carcinoma in situ (DCIS).    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups, or you can choose your study group. </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Personalized, Risk-Based Screening</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Screening recommendations based on comprehensive, personal risk assessment</li> <li class="seamTextUnorderedListItem">Saliva sample genetic test</li> <li class="seamTextUnorderedListItem">Online, annual health questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard Annual Screening</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Screening recommendation for annual mammograms</li> <li class="seamTextUnorderedListItem">Online, annual health questionnaires</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Personalized risk-based screening will take multiple risk factors into consideration, including genetic markers, to determine how often you should have a mammogram.</li> <li class="seamTextUnorderedListItem">This study will help researchers learn if risk-based screening, which helps women learn more about their personal breast cancer risk, is less stressful and as successful at detecting breast cancer as annual screening. </li> <li class="seamTextUnorderedListItem">This study is available in English and Spanish.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02620852' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.thewisdomstudy.org/' target='_blank'>WISDOM: Study Information Page</a> </li></ul>
See more
3

NEAREST SITE: 3 miles
University of California, San Francisco
San Francisco,CA

VISITS: Coincides with surgery

PHASE: NA

NCT ID: NCT01570998

Targeted Intraoperative Radiotherapy (TARGIT) Registry Trial

Targeted Intraoperative Radiotherapy United States (TARGIT-US) Phase IV Registry Trial: A Registry Trial of Targeted Intraoperative Radiation Therapy Following Breast-conserving Surgery Scientific Title

Purpose
To study the effects (good and bad) of targeted intraoperative radiotherapy.
Who is this for?
Women 45 and older, with stage I or stage II estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who will have a lumpectomy (breast conserving surgery) and are considered low risk for a local recurrence.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Intraoperative radiotherapy as a single dose after breast conserving surgery (lumpectomy)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Participants may receive whole breast radiation, if indicated.</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation is used to kill any breast cancer cells that may not have been removed during surgery.</li> <li class="seamTextUnorderedListItem">Targeted intraoperative radiotherapy is delivered during surgery immediately after the tumor has been removed. This allows the radiation to accurately target the tissue surrounding the tumor, where the risk of recurrence is highest.</li> <li class="seamTextUnorderedListItem">It takes about 20-35 minutes to provide intraoperative radiotherapy.</li> <li class="seamTextUnorderedListItem">The Targeted Intraoperative Radiotherapy Trial (TARGIT), will follow women who receive this type of radiation therapy for five years, allowing researchers to study its effectiveness and side effects.</li> <li class="seamTextUnorderedListItem">If indicated, you will also receive whole breast radiation.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01570998' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/radiation/intraoperative' target='_blank'>Breastcancer.org: Intraoperative Radiation Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://scholar.google.com/scholar?q=intraoperative+radiation+therapy+breast+cancer&hl=en&as_sdt=0&as_vis=1&oi=scholart&sa=X&ei=V-NpUMOGOObmiwKC2IHQDg&ved=0CCkQgQMwAA' target='_blank'>Google Scholar: Intraoperative Radiation Therapy Breast Cancer</a> </li></ul>
See more
4

NEAREST SITE: 3 miles
UCSF Breast Care Center
San Francisco,CA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT03053193

The FLEX Registry: MammaPrint Testing With or Without BluePrint Testing For People With Stage I-III Breast Cancer

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry) Scientific Title

Purpose
To create a large registry of tumor samples to help researchers find new cancer biomarkers and design future clinical trials.
Who is this for?
People with stage I, stage II, or stage III breast cancer who received MammaPrint testing, with or without BluePrint genomic testing, of their tumor.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> For this data collection registry, you will: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide a sample of your tumor (taken during a routine procedure)</li> <li class="seamTextUnorderedListItem">Allow information about your breast cancer treatment to be included in the registry</li> <li class="seamTextUnorderedListItem">Information will be collected from you when you enroll in the registry, during treatment, 1 year after treatment ends; and 2, 5, and 10 years after your diagnosis</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The FLEX Registry will create a database of clinical and genomic information collected from patients who have had their tumor tested with MammaPrint, with or without BluePrint genomic testing. </li> <li class="seamTextUnorderedListItem">MammaPrint is a diagnostic test done on a tumor sample to help guide treatment decisions. The results tell you and your doctor if you have a low or high risk of recurrence. </li> <li class="seamTextUnorderedListItem">BluePrint is a molecular test done on the tumor sample to further classify your risk of recurrence.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03053193' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.agendia.com/clinical-trials/ongoing-studies/' target='_blank'>Trial Sponsor Information Page: FLEX Registry</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/diagnosis/genomic_assays' target='_blank'>Breastcancer.org: Tumor Genomic Assay Testing</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/testing/types/mammaprint' target='_blank'>Breastcancer.org: MammaPrint Test</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.agendia.com/our-tests/mammaprint/' target='_blank'>Agendia Information Page: MammaPrint Test</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.agendia.com/diagnostic-products/blueprint.html#' target='_blank'>Agendia Information Page: BluePrint Test</a> </li></ul>
See more
5

NEAREST SITE: 7 miles
xCures
Oakland,CA

VISITS: Coincides with routine care

PHASE: NA

NCT ID: NCT05461430

Malignant Fluid Test to Predict Response to Treatment for Breast Cancer

Mass Response of Malignant Fluid Cells as a Biomarker for Rapid Therapy Guidance Scientific Title

Purpose
To study if a mass response test can predict your cancer's response to potential treatments.
Who is this for?
People with stage I, stage II, stage III, or metastatic (stage IV) breast cancer that have malignant fluid.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> Additional malignant fluid will be collected as part of a standard of care procedure.</p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Malignant fluid is the build up of fluid and cancer cells in your body.</li> <li class="seamTextUnorderedListItem">A cancer cell's mass response (weight change) indicates when a cancer cell begins responding to a drug before it dies.</li> <li class="seamTextUnorderedListItem">The results from the mass response test may be used by your doctor to choose your next treatment(s).</li> <li class="seamTextUnorderedListItem">Additional malignant fluid will be collected as part of a standard of care procedure.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05461430' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.travera.com/clinical-study-summary' target='_blank'>Travera Trial Information Page: TRV-003</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.travera.com/technology' target='_blank'>Travera: Mass Response Test</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.thoracic.org/patients/patient-resources/resources/malignant-pleural-effusions.pdf' target='_blank'>American Thoracic Society: Malignant Fluid</a> </li></ul>
See more
6

NEAREST SITE: 252 miles
Sansum Clinic - Ridley-Tree Cancer Center (Solvang)
Solvang,CA

VISITS: Coincides with routine care

PHASE: NA

NCT ID: NCT04875351

Breast Cancer Index (BCI) Registry for Women with Stage I-III HR+ Breast Cancer

Breast Cancer Index (BCI) Registry Scientific Title

Purpose
To determine if you should receive additional hormone therapy and to study the long-term anti-cancer activity and risk of recurrence after treatment with hormone therapy.
Who is this for?
Women with stage I, stage II, or stage III hormone receptor positive (ER+ and/or PR+) breast cancer who have completed 4-7 years of hormone therapy. If you have positive lymph nodes, you must have 1-3 positive lymph nodes.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast Cancer Index (BCI) tumor test</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The information collected by the Breast Cancer Index (BCI) test will help your doctor determine if you should receive 5 additional years of hormone therapy based on your risk of recurrence.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04875351' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancerindex.com/' target='_blank'>Biotheranostics Test Information Page: Breast Cancer Index Test</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/breast-cancer-index-test' target='_blank'>Breastcancer.org: Breast Cancer Index Test</a> </li></ul>
See more
7

NEAREST SITE: 339 miles
John Wayne Cancer Institute, Providence Saint John's Health Center
Santa Monica,CA

VISITS: 1 visit that coincides with surgery

PHASE: NA

NCT ID: NCT04603209

A Registry and IORT Radiation Therapy During Lumpectomy for DCIS and Stage I-III Breast Cancer

Research Registry for Intra-Operative Radiotherapy (IORT) During Breast Conserving Surgery in Patients With in Situ and Early Stage Breast Cancer Scientific Title

Purpose
To develop a registry that will allow researchers to study and compare the long-term safety and anti-cancer activity of giving one dose of radiation therapy (IORT) during a lumpectomy to standard of care radiation therapy.
Who is this for?
People with DCIS, stage I, stage II, or stage III breast cancer who are planning to have a lumpectomy (breast conserving surgery).    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">IORT (Intraoperative radiation therapy), one time during lumpectomy (breast conserving surgery)</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A lumpectomy is sometimes called a partial mastectomy. </li> <li class="seamTextUnorderedListItem">Typically, a lumpectomy (breast conserving surgery) is followed by 4 to 6 weeks of daily radiation therapy.</li> <li class="seamTextUnorderedListItem">In this trial, you will receive intraoperative radiation therapy (IORT) one time during your lumpectomy. </li> <li class="seamTextUnorderedListItem">IORT delivers a high dose of radiation during surgery to the area in the breast where the tumor was removed. This means you only receive one dose, and it may cause less damage to the healthy tissue around the tumor. </li> <li class="seamTextUnorderedListItem">This trial will also create a data registry of people receiving IORT so that researchers can study the long-term safety and anti-cancer activity of this type of radiation therapy.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04603209' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/20131203' target='_blank'>Breastcancer.org: Studies Show Risks and Benefits of Intraoperative Radiation Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cdc.gov/cancer/npcr/value/registries.htm' target='_blank'>CDC: How Cancer Registries Work</a> </li></ul>
See more
8

NEAREST SITE: 375 miles
Knowledge Research Center
Orange,CA

VISITS: 2 times within 6 months, then 3 times within 2 years

PHASE: NA

NCT ID: NCT04638751

Stool and Blood Sample Bank to Develop New Treatments for Triple Negative Breast Cancer

ARGONAUT: Development and Analysis of a Blood and Stool Sample Bank for Cancer Patients, Enabling the Systematic Study of the Effect of Gut Microbiomes on Response to Treatment Scientific Title

Purpose
To collect stool and blood samples to study gut microbiomes, study cancer biomarkers, and develop new treatments.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer planning to receive their next treatment.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stool and blood samples, 2 times within 6 months</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stool samples will be used to study your gut microbiome, which are the microorganisms that live in your digestive system. Drugs that target your microbiome may be helpful to treat cancer.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04638751' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.healthline.com/nutrition/gut-microbiome-and-health' target='_blank'>Healthline: Gut Microbiome</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.aiche.org/resources/publications/cep/2020/october/developing-precision-microbiome-medicines' target='_blank'>American Institute of Chemical Engineers: Developing Precision Microbiome Medicines</a> </li></ul>
See more
9

NEAREST SITE: 680 miles
Swedish Cancer Institute
Seattle,WA

VISITS: 1 visit

PHASE: NA

NCT ID: NCT02701244

Breast Seed Implant Radiation Treatment for Women with DCIS or Early-Stage Breast Cancer

A Multicenter Registry Study of Breast Microseed Treatment for Early Stage Breast Cancer Scientific Title

Purpose
To study the safety and effects (good and bad) of a permanent breast seed implant (PBSI) radiation technique for treating women with DCIS or early-stage breast cancer.
Who is this for?
Women who are at least 50 years of age and who have recently had a lumpectomy for DCIS or stage I, stage II, or stage III breast cancer. You must also have had either an axillary node dissection or sentinel lymph node biopsy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will undergo the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pre-planning of implantation using CT scan </li> <li class="seamTextUnorderedListItem">Permanent breast seed implantation, an out-patient procedure using local anesthesia and light sedation</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Permanent breast seed implant (PBSI) involves implanting radioactive seeds in a portion of the breast, allowing the patient to live a normal life while the seeds deliver the prescribed radiation to the breast.</li> <li class="seamTextUnorderedListItem">Researchers think that PBSI is a safe and effective alternative to traditional forms of radiation for women who have had a lumpectomy and lymph node dissection or sentinel lymph node biopsy.</li> <li class="seamTextUnorderedListItem">This trial will also create a data registry of women receiving a PBSI so that researchers can study the long-term safety and anti-cancer activity of this type of radiation therapy.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02701244' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.concureoncology.com/clinical-pathway' target='_blank'>Concure Oncology Information Page: Breast Microseed Treatment</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/radiation/internal-radiation-therapy-brachytherapy.html' target='_blank'>American Cancer Society: Internal Radiation Therapy</a> </li></ul>
See more
10

NEAREST SITE: 764 miles
Providence St. Patrick Hospital Montana Cancer Center
Missoula,MT

VISITS: One visit every year

PHASE: NA

NCT ID: NCT02012699

iCaRe2: Integrated Cancer Data Repository for Cancer Research

Integrated Cancer Repository for Cancer Research Scientific Title

Purpose
To study cancer risk factors, cancer prevention, early detection and personalized cancer treatments by creating a data registry and biobank.
Who is this for?
People who have or are at risk for developing breast cancer and other cancers.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> This is a data collection (registry) study. You will: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide biospecimens (blood, urine, tissue) for the biobank</li> <li class="seamTextUnorderedListItem">Complete questionnaires, once a year</li> <li class="seamTextUnorderedListItem">Participate in follow-up visits with your healthcare provider, once a year</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Research sites will implement and maintain a comprehensive data and biospecimen bank known as the Integrated Cancer Repository for Cancer Research (iCaRe2). </li> <li class="seamTextUnorderedListItem">Participants will provide blood, urine and tissue samples for the biobank. </li> <li class="seamTextUnorderedListItem">The data registry and biospecimen bank is made available for research on cancer and other chronic diseases.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02012699' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://icare2project.org' target='_blank'>iCaRe2 Project</a> </li></ul>
See more
11

NEAREST SITE: 996 miles
Texas Tech University Health Sciences Center- El Paso
El Paso,TX

VISITS: Coincides with surgery

PHASE: NA

NCT ID: NCT04362462

Biomarker Testing for Hispanic and Latino Women with Stage I-IV Triple Negative Breast Cancer

Genomic/Molecular Profiling of Residual Disease After Neoadjuvant Chemotherapy in Hispanic/ Latino Women With Triple-negative Breast Cancer Scientific Title

Purpose
To study the cause of treatment resistance in triple negative breast cancer and how to improve treatment for triple negative breast cancer.
Who is this for?
Hispanic and Latino women with stage I, stage II, or stage III triple negative (ER-, PR-, HER2-) breast cancer who are planning to receive chemotherapy before surgery (neoadjuvant) or stage IV (metastatic) triple negative breast cancer. If you have metastatic breast cancer, you must have developed metastatic disease during treatment within 24 months of completing standard treatment.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biomarker testing of tumor</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biomarker testing, also called genomic or molecular profiling, refers to tests for mutations and other biomarkers.</li> <li class="seamTextUnorderedListItem">Neoadjuvant therapy is when you receive treatment, like chemotherapy, before surgery. Doctors use it to shrink tumors and to see how your cancer responds to the given therapies.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04362462' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org/' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/other-breast-cancer-gene-protein-blood-tests.html' target='_blank'>American Cancer Society: Breast Caner Testing</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/precision-medicine.html' target='_blank'>American Cancer Society: Precision or Personalized Medicine</a> </li></ul>
See more
12

NEAREST SITE: 1251 miles
Hays Medical Center Dreiling-Schmidt Cancer Institute
Hays,KS

VISITS: 1 visit

PHASE: NA

NCT ID: NCT02302742

A Registry for People with Triple Negative or ER-Low, HER2- Breast Cancer or an Inherited BRCA1/2 or Certain Other Mutations

PROspective Evaluation of GErmline Mutations, Cancer Outcome and Tissue Biomarkers: A Registry for Patients With Triple Negative Breast Cancer and Germline Mutations (PROGECT) Scientific Title

Purpose
To learn more about the relationship between genetic mutations and cancer outcomes.
Who is this for?
People with inherited BRCA1/2 mutations or certain other genetic mutations (see list below) and people with stage I, stage II, stage III, or stage IV triple negative (ER-, PR-, HER2-) or ER-Low (1%-10% ER) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> This is a data collection (registry) study. You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">1 blood test</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that tests positive for 1%-10% estrogen receptors is called ER-Low.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with triple negative as well as ER-Low breast cancer.</li> <li class="seamTextUnorderedListItem">Studies have found a relationship between triple negative breast cancer and inherited BRCA1 and BRCA2 mutations. </li> <li class="seamTextUnorderedListItem">Targets or mutations: BRCA1, BRCA2, PTEN, P53, and PALB2</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02302742' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancer.net/cancer-types/hereditary-breast-and-ovarian-cancer' target='_blank'>ASCO: Hereditary Breast and Ovarian Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='http://ww5.komen.org/BreastCancer/InheritedGeneticMutations.html' target='_blank'>Susan G. Komen: Inherited Gene Expressions</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li><li class='seamTextUnorderedListItem'><a href='https://ghr.nlm.nih.gov/condition/breast-cancer' target='_blank'>NIH Genetics Home Reference: Breast Cancer</a> </li></ul>
See more
13

NEAREST SITE: 1502 miles
The University of Kansas Cancer Center, Westwood Campus
Kansas City,KS

VISITS: 5 visits within 6 months

PHASE: NA

NCT ID: NCT04821570

Production of Antibodies Against COVID-19 After COVID-19 Vaccination in People with Breast Cancer

Cancer Therapy and Immunogenicity of COVID Vaccine (CANINE Trial) Scientific Title

Purpose
To measure the production of antibodies against COVID-19 during breast cancer treatment.
Who is this for?
People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are receiving treatment.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">COVID-19 vaccine</li> <li class="seamTextUnorderedListItem">Blood tests, 5 times within 6 months</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The COVID-19 vaccine induces production of antibodies against the COVID-19 virus.</li> <li class="seamTextUnorderedListItem">The production of antibodies can be measured in blood.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04821570' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.kucancercenter.org/cancer-clinical-trials/find-trial/clinical-trial-results/STUDY00146880?reloadts=1624565410750' target='_blank'>University of Kansas Cancer Center: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/medical-professionals/cancer/news/poor-antibody-response-for-covid-vaccine-in-patients-with-cancer/mac-20531398' target='_blank'>Mayo Clinic: Antibody Response Following the COVID-19 Vaccine in People Receiving Treatment for Cancer</a> </li></ul>
See more
14

NEAREST SITE: 1509 miles
UT Southwestern
Dallas,TX

VISITS: 2 visits within 2 months, then every 6 months for 5 years

PHASE: NA

NCT ID: NCT05245812

Robotic Nipple Sparing Mastectomy for Women with DCIS, Stage I-III Breast Cancer, or at High Risk for Breast Cancer

Safety and Feasibility of Robotic Single-port (SP) Nipple Sparing Mastectomy: A Single Institution, Single Arm Pilot Trial Scientific Title

Purpose
To study the safety and effects (good and bad) of nipple sparing mastectomy with da Vinci single port (SP) Surgical System.
Who is this for?
Women with DCIS, stage I, stage II, or some stage III breast cancer, or at high risk for breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Nipple sparing mastectomy with da Vinci single port (SP) Surgical System</li> <li class="seamTextUnorderedListItem">Immediate breast reconstruction with tissue expanders/implants and acellular dermal matrix (Alloderm®)</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The da Vinci single port (SP) Surgical System is a system designed for surgeons to perform minimally invasive surgery, such as nipple sparing mastectomy.</li> <li class="seamTextUnorderedListItem">The da Vinci SP Surgical System is approved for use during other surgeries.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05245812' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.intuitive.com/en-us/products-and-services/da-vinci/systems/sp' target='_blank'>Intuitive: The Da Vinci SP Surgical System</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/consider-cx-characteristics-for-nipple-sparing-mx' target='_blank'>Breastcancer.org: Nipple Sparing Mastectomy</a> </li></ul>
See more
15

NEAREST SITE: 1539 miles
Mayo Clinic Health System Mankato
Mankato,MN

VISITS: At least 2 visits

PHASE: NA

NCT ID: NCT05662345

Circulating Tumor Cells Test to Make Treatment Decisions for Metastatic Breast Cancer

ACT-MBC: A Prospective Observational Impact Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer Scientific Title

Purpose
To study whether the CELLSEARCH® Circulating Tumor Cell Test helps doctors make treatment decisions and determine response to treatment.
Who is this for?
People with metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) or triple negative (ER-, PR-, HER2-) breast cancer. If you have ER+, HER2- breast cancer, you must have received at least 1 line of therapy for metastatic disease.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood sample for CELLSEARCH® Circulating Tumor Cell Test</li> </ul> <p class="seamTextPara"> followed within 1.5 years by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Imaging scans, at least 1 time</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Circulating tumor cells (CTCs) are cancer cells from a tumor that circulate in the bloodstream.</li> <li class="seamTextUnorderedListItem">The CELLSEARCH® Circulating Tumor Cell Test can detect CTCs in your blood to help your doctor make treatment decisions and determine your response to treatment.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05662345' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/ctc/' target='_blank'>Metastatic Trial Talk: Circulating Tumor Cell Testing</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cellsearchctc.com/about-cellsearch/what-is-cellsearch-ctc-test' target='_blank'>Menarini Silicon Biosystems: CELLSEARCH® Circulating Tumor Cell Test</a> </li></ul>
See more
16

NEAREST SITE: 1548 miles
Mary Greeley Medical Center
Ames,IA

VISITS: 1 visit every 3 months for 1.5 years

PHASE: NA

NCT ID: NCT05568472

Monitoring Symptoms to Help Women Continue Taking Hormone Therapy for Stage I-III Breast Cancer

A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence With Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN) Scientific Title

Purpose
To study if reporting symptoms by email, text, or phone helps women continue taking hormone therapy.
Who is this for?
Premenopausal or perimenopausal women with stage I, stage II, or stage III hormone receptor positive (ER+ and/or PR+) breast cancer who are receiving or planning to receive hormone therapy. You must have received surgery within 2 weeks of beginning this trial.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive standard of care hormone therapy</li> <li class="seamTextUnorderedListItem">Receive health education materials</li> <li class="seamTextUnorderedListItem">Attend clinic visits, every 3 months for 1.5 years</li> <li class="seamTextUnorderedListItem">Report symptoms, by email, text, or phone, weekly for 6 months, then monthly for 1 year</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive standard of care hormone therapy</li> <li class="seamTextUnorderedListItem">Receive health education materials</li> <li class="seamTextUnorderedListItem">Attend clinic visits, every 3 months for 1.5 years</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional Procedures</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Hormone therapy is a common treatment for hormone receptor positive (HR+) breast cancer.</li> <li class="seamTextUnorderedListItem">Hormone therapy can cause side effects which may cause some women to stop treatment early. Asking about symptoms may help women continue taking hormone therapy.</li> <li class="seamTextUnorderedListItem">Health education materials contain information about breast cancer, side effects of breast cancer medicines, and ways to help with heart health.</li> <li class="seamTextUnorderedListItem">Questionnaires can be completed in English or Spanish.</li> <li class="seamTextUnorderedListItem">Premenopausal and perimenopausal women will also be given a drug that will put women in temporary menopause.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05568472' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/20070906b' target='_blank'>Breastcancer.org: Side Effects of Hormone Therapy</a> </li></ul>
See more
17

NEAREST SITE: 1615 miles
Mayo Clinic in Rochester
Rochester,MN

VISITS: At least 3 visits including surgery; may require hospitalization

PHASE: NA

NCT ID: NCT04692337

Ommaya Reservoir Placement to Collect CSF Samples for Brain Metastasis

Ommaya Reservoir Placement for Brain Tumor Biomarker Access Scientific Title

Purpose
To study the safety and effects (good and bad) of Ommaya reservoir placement that will be used to collect and study CSF samples.
Who is this for?
People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to undergo brain surgery.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain surgery to place Ommaya reservoir</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Collection of CSF from Ommaya reservoir, 2 or more times</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for schedule.</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">An Ommaya reservoir will be placed during brain surgery.</li> <li class="seamTextUnorderedListItem">Ommaya reservoirs are very small plastic devices put under the scalp to give access to cerebrospinal fluid (CSF), the fluid or liquid surrounding your brain and spinal cord.</li> <li class="seamTextUnorderedListItem">CSF samples will be used to study brain cancer activity and develop new brain cancer treatments.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04692337' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/cancer-care/patient-education/faq-about-ommaya-reservoirs-and-ommaya-taps' target='_blank'>Memorial Sloan Kettering Cancer Center: Ommaya Reservoir</a> </li></ul>
See more
18

NEAREST SITE: 1615 miles
Mayo Clinic in Rochester
Rochester,MN

VISITS: 2 visits

PHASE: NA

NCT ID: NCT04692324

Registry of CSF Biomarkers from Lumbar Punctures for Brain Metastasis

Cerebrospinal Fluid Biomarkers for Brain Tumors Scientific Title

Purpose
To collect samples of CSF to study brain tumor biomarkers and develop new ways to diagnose, monitor, and treat brain tumors.
Who is this for?
People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis).    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lumbar puncture to collect CSF, 2 or more times</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional Procedures</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Surveys</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule.</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A lumbar puncture, also known as a spinal tap, is a procedure to collect a sample of fluid that surrounds your brain and spinal cord, called cerebrospinal fluid (CSF).</li> <li class="seamTextUnorderedListItem">Biomarkers can indicate the presence or severity of brain tumors.</li> <li class="seamTextUnorderedListItem">You may choose to undergo additional lumbar punctures to collect additional CSF samples.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04692324' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>
See more
19

NEAREST SITE: 1621 miles
MD Anderson in The Woodlands
The Woodlands,TX

VISITS: Coincides with routine care

PHASE: NA

NCT ID: NCT00477100

Breast Cancer Registry for Inflammatory and Other Types of Breast Cancer

Inflammatory Breast Cancer (IBC) Registry Scientific Title

Purpose
To collect and study blood and tissue samples and clinical data from people with newly diagnosed and untreated breast cancer, including inflammatory breast cancer.
Who is this for?
People with newly diagnosed and untreated stage I, stage II, stage III, or stage IV (metastatic) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Additional blood drawn during a routine blood draw</li> <li class="seamTextUnorderedListItem">Core, breast tissue, and skin biopsy (performed for diagnosis)</li> <li class="seamTextUnorderedListItem">Medical history interview</li> <li class="seamTextUnorderedListItem">Clinical data collected from your medical records</li> <li class="seamTextUnorderedListItem">Photographs of both breasts</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Inflammatory breast cancer is a rare, aggressive type of breast cancer in which the cancer cells block the lymph vessels in the skin, causing the breast to appear red and swollen.</li> <li class="seamTextUnorderedListItem">Researchers have not yet identified any genes or other risk factors that they could use to design better treatments for inflammatory breast cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT00477100' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2006-1072.html' target='_blank'>MD Anderson Cancer Center: Study Website</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancer.gov/cancertopics/factsheet/sites-types/ibc' target='_blank'>NCI: Inflammatory Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/symptoms/types/inflammatory' target='_blank'>Breastcancer.org: Inflammatory Breast Cancer</a> </li></ul>
See more
20

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: 1-2 visits over 1-2 days

PHASE: NA

NCT ID: NCT04678414

A Fertility Survey of Women with Stage I, Stage II, or Stage III Breast Cancer

Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer Scientific Title

Purpose
To study how women decide whether or not to try to have a baby after a breast cancer diagnosis.
Who is this for?
Women who were age 45 or younger when diagnosed with stage I, stage II, or stage III breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">One 90-minute focus group</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A 15-30 minute online survey, twice</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">One telephone survey</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The researchers hope to use the information gathered to help people with cancer make decisions about cancer treatment and family planning.</li> <li class="seamTextUnorderedListItem">This study is also enrolling people diagnosed with other types of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04678414' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2018-0477.html' target='_blank'>MD Anderson Cancer Center: Study Website</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ccrcal.org/learn-about-ccr/about-cancer-registries/' target='_blank'>California Cancer Registry: About the California Cancer Registry</a> </li></ul>
See more
21

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: 1 visit

PHASE: NA

NCT ID: NCT02918474

A Tool to Help Women Decide Whether to Have a Contralateral Preventative Mastectomy

Decision Making Tool for Contralateral Prophylactic Mastectomy Scientific Title

Purpose
To learn more about an online decision support tool that helps you and your doctor discuss whether or not you should have a contralateral prophylactic mastectomy (removal of breast that does not have cancer).
Who is this for?
Women recently diagnosed with DCIS or stage I, stage II, or stage III breast cancer and are seeing a surgeon at MD Anderson Cancer Center.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will complete a questionnaire before and after using the decision support tool.</p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">If you take part in this study, you will complete a questionnaire about the decision support tool.</li> </ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02918474' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
22

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05649072

Genetic Testing and Counseling for Women in Texas

Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics. Scientific Title

Purpose
To provide genetic testing and counseling to underserved women at risk for breast cancer.
Who is this for?
Women ages 40 to 74 who live in Texas, do not have health insurance, and are planning to receive a mammogram through the Project VALET program.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Genetic testing and counseling</li> <li class="seamTextUnorderedListItem">Questionnaire</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will provide a saliva sample for genetic testing when you arrive at your Project VALET mammogram appointment.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05649072' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/about-md-anderson/business-legal/office-of-health-policy/project-valet.html#:~:text=Project%20VALET%20(Providing%20Valuable%20Area,are%20patients%20in%20participating%20clinics.' target='_blank'>MD Anderson Cancer Center: Project VALET Mammogram Screening</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/genetic-testing' target='_blank'>Breastcancer.org: Genetic Testing</a> </li></ul>
See more
23

NEAREST SITE: 1678 miles
UW Health Oncology Clinics
Madison,WI

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05609435

REASSURE Follow-Up Care After Treatment for Stage I HR+, HER2- Breast Cancer

Evaluating a Novel Follow-up Intervention to Improve the Delivery of Follow-up Care for Low-Risk Breast Cancer Survivors in Wisconsin Scientific Title

Purpose
To study whether REASSURE follow-up care improves survivors' preparedness for survivorship.
Who is this for?
Women with stage I hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer diagnosed between 6 months and 2 years ago who have completed treatment. You must not have received chemotherapy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">REASSURE follow-up care</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care follow-up care</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">REASSURE follow-up care is comprised of three components: 1) the REASSURE patient-reported outcome (PRO) questionnaire to assess your symptoms/concerns, 2) a recommendation for or against a follow-up visit based on your symptoms/concerns, and 3) REASSURE survivorship messaging, including reassurance about the low recurrence risk, an overview of what to expect from follow-up, and steps you can take to reduce cancer risk.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05609435' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.net/cancer-types/breast-cancer/follow-care-and-monitoring#:~:text=Your%20follow%2Dup%20care%20may,treated%20for%20curable%20breast%20cancer.' target='_blank'>ASCO: Breast Cancer Follow-up Care and Monitoring</a> </li></ul>
See more
24

NEAREST SITE: 1906 miles
Clinical Site
Covington,LA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05697198

OmniSeq Test to Detect Biomarkers and Mutations in People with Advanced Breast Cancer

PRospective rEgistry OF Advanced Stage cancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations Using the OmniSeq Test and Creation of a Biobank From Community Cancer Clinics in the United States to Address Disparities in Precision Medicine Scientific Title

Purpose
To study the ability of the OmniSeq Test to detect biomarkers and mutations compared to a liquid biopsy.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood and/or tissue samples for OmniSeq Test</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The OmniSeq Test is a genomic test that detects biomarkers and mutations for many types of cancer.</li> <li class="seamTextUnorderedListItem">The OmniSeq Test may help your doctor select your treatment based on detected biomarkers and mutations.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05697198' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://oncology.labcorp.com/cancer-care-team/test-menu/omniseq-insight' target='_blank'>Labcorp: OmniSeq Test</a> </li></ul>
See more
25

NEAREST SITE: 2054 miles
University of Michigan Rogel Cancer Center
Ann Arbor,MI

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05700006

Effects of Hormone Therapy vs. No Hormone Therapy for Breast Cancer and Breast Cancer Prevention on Aging and the Microbiome

An Observational Study of Women With Breast Cancer Examining the Effect of Endocrine Therapy on Aging Scientific Title

Purpose
To study the effects of hormone therapy on biomarkers of aging and the microbiome.
Who is this for?
Women with stage 0 (DCIS), stage I, stage II, or stage III breast cancer or women at high risk of developing breast cancer. You must not have received treatment with an aromatase inhibitor for breast cancer or breast cancer prevention.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be assigned to 1 of 3 groups depending on your situation: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Over 65 and Planning to Receive Hormone Therapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Physician's choice of anastrozole (Arimidex®), exemestane (Aromasin®), or letrozole (Femara®)</li> <li class="seamTextUnorderedListItem">3 stool samples, questionnaires, blood draws</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Over 65 and Not Planning to Receive Hormone Therapy (Control Group)</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">3 stool samples, questionnaires, blood draws</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3: Under 65 and Planning to Receive Hormone Therapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Physician's choice of anastrozole (Arimidex®), exemestane (Aromasin®), or letrozole (Femara®)</li> <li class="seamTextUnorderedListItem">3 stool samples, questionnaires, blood draws</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The microbiome is the collection of microorganisms (bacteria) living in your digestive tract.</li> <li class="seamTextUnorderedListItem">Anastrozole (Arimidex®), exemestane (Aromasin®), and letrozole (Femara®) are types of hormone therapy called aromatase inhibitors. Aromatase inhibitors block some production of estrogen that helps cancer grow.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05700006' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/arimidex' target='_blank'>Breastcancer.org: Anastrozole (Arimidex®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/aromasin' target='_blank'>Breastcancer.org: Exemestane (Aromasin®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/femara' target='_blank'>Breastcancer.org: Letrozole (Femara®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.insideprecisionmedicine.com/topics/oncology/breast-cancer/probiotic-bacteria-may-improve-efficacy-of-endocrine-targeted-therapies-for-breast-cancer/' target='_blank'>Inside Precision Medicine: Breast Cancer Treatments and the Microbiome</a> </li></ul>
See more
26

NEAREST SITE: 2108 miles
Mount Carmel West Hospital
Columbus,OH

VISITS: Coincides with surgery

PHASE: NA

NCT ID: NCT03536897

Radiation During Breast Cancer Surgery in Women Age 65 and Older

Intraoperative Radiation Therapy (IORT) Following Breast Conserving Surgery for Early Stage Breast Cancer Registry Scientific Title

Purpose
To develop a registry that will allow researchers to study the 5-year risk of a local breast cancer recurrence after intraoperative radiation therapy (IORT).
Who is this for?
Women age 65 or older with stage II or stage III low- risk breast cancer who will be treated with partial mastectomy (lumpectomy) and radiation during surgery.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">IORT (Intraoperative radiation), during surgery</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Intraoperative radiation therapy (IORT) is given right after the tumor has been removed while you are still in the operating room.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03536897' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/intraoperative-radiation-therapy/about/pac-20385150' target='_blank'>Mayo Clinic: Intraoperative radiation therapy (IORT)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.tricitymed.org/2016/10/iort-breast-cancer-treatment-primer/' target='_blank'>Tricity Medicine: IORT as Breast Cancer Treatment: A Primer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.uptodate.com/contents/overview-of-the-approach-to-early-breast-cancer-in-older-women' target='_blank'>UpToDate: Overview of the approach to early breast cancer in older women</a> </li></ul>
See more
27

NEAREST SITE: 2108 miles
Ohio State University Comprehensive Cancer Center
Columbus,OH

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05503251

Improving Quality of Life and Cognitive Function After Radiation Therapy for People with Brain Metastases

Effect of Early Integrated Neuropsychological Care in Patients With Brain Metastases - A Phase 2 Randomized Controlled Trial Scientific Title

Purpose
To study if neuropsychological evaluations can improve quality of life or cognitive function after radiation.
Who is this for?
People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive radiation. You must not have previously received whole brain radiation therapy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neuropsychological evaluations, 3 times within 6 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No neuropsychological evaluations</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional Procedures</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Quality of life refers to the overall enjoyment of life. It holds varying meanings for different people and may evolve over time. For some individuals it implies autonomy, empowerment, capability, and choice; for others, security, social integration, or freedom from stress or illness.</li> <li class="seamTextUnorderedListItem">Neuropsychological evaluation is used to examine the cognitive (thinking) consequences of brain damage, brain disease, and severe mental illness.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05503251' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>
See more
28

NEAREST SITE: 2199 miles
Medical Center, Navicent Health
Macon,GA

VISITS: Every 6 months for 2 years, then once a year for 8 years

PHASE: NA

NCT ID: NCT04595435

A Registry and IORT Radiation Therapy During Lumpectomy for Women 55+ with Stage I ER+, HER2- Breast Cancer

Prospective Registry of Intraoperative Radiation Therapy Using Low Energy X-ray for Breast Cancer at Medical Center, Navicent Health Scientific Title

Purpose
To create a registry to study the effects (good and bad) of using intraoperative radiation therapy (IORT) during a lumpectomy (breast conserving surgery).
Who is this for?
Women, 55 or older, with stage I, node-negative, estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who will be receiving (or have received within the last 6 months) radiation and a lumpectomy at Navicent Health in Macon, Georgia.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be assigned to 1 of 2 groups depending on whether you have already received radiation therapy and surgery: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Radiation therapy and registry</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">IORT (Intraoperative radiation therapy), one time during your lumpectomy (breast conserving surgery)</li> <li class="seamTextUnorderedListItem">Quality of life questionnaires, before and after surgery </li> <li class="seamTextUnorderedListItem">Inclusion in data registry </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Registry only, for women who had IORT and lumpectomy within the last 6 months</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Quality of life questionnaires </li> <li class="seamTextUnorderedListItem">Inclusion in data registry</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Intraoperative radiation therapy (IORT) is given right after the tumor has been removed while you are still in the operating room.</li> <li class="seamTextUnorderedListItem">The machine used to give the IORT in this trial is called The Xoft® System.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04595435' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/iort-during-lx-vs-whole-breast-for-early-bc' target='_blank'>Breastcancer.org: Intraoperative Radiation Therapy During Lumpectomy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/types-of-breast-cancer/invasive-breast-cancer.html' target='_blank'>American Cancer Society: Invasive Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.xoftinc.com/electronic-brachytherapy-ebx.html' target='_blank'>Xoft Medical Device Information Page: Xoft® Axxent® Electronic Brachytherapy (eBx®) System®</a> </li></ul>
See more
29

NEAREST SITE: 2299 miles
Roswell Park Cancer Institute
Buffalo,NY

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT04526587

Studying CDK 4/6 Inhibitors in People with Stage I-IV HR+, HER2- Breast Cancer

The Roswell Park Ciclib Study: A Prospective Study of Biomarkers and Clinical Features of Advanced/Metastatic Breast Cancer Treated With CDK4/6 Inhibitors Scientific Title

Purpose
To study how breast cancer develops resistance to CDK 4/6 inhibitors and how to predict response to CDK 4/6 inhibitors.
Who is this for?
People with metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer or peoole with stage I, stage II, or stage IV hormone receptor positive (ER+ and/or PR+), HER2 negative (HER-) node positive breast cancer. You must currently be receiving treatment with or completed treatment with a CDK 4/6 inhibitor.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Provide blood, tissue, and biopsy samples</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CDK 4/6 inhibitors may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04526587' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/what-are-cdk46-inhibitors' target='_blank'>Breastcancer.org: CDK 4/6 Inhibitors</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/cdk-inhibitor-updates/?utm_medium=email&utm_source=subscribers&utm_campaign=Dec2022&utm_content=Email122022' target='_blank'>Metastatic Trial Search: CDK Inhibitors</a> </li></ul>
See more
30

NEAREST SITE: 2314 miles
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem,NC

VISITS: May require hospitalization

PHASE: NA

NCT ID: NCT05395936

Studying Breast Skin Temperature During Mastectomy for People with Stage I-III Breast Cancer

Mastectomy Flap Temperature and Clinical Implications Scientific Title

Purpose
To measure breast skin temperatures during mastectomies to improve the care of people receiving breast surgery.
Who is this for?
Women with stage I, stage II, or stage III breast cancer who are planning to receive a mastectomy (one or both breasts) at Wake Forest Baptist Health System.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care mastectomy</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Mastectomy is surgery to remove the breast.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05395936' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/surgery/mastectomy' target='_blank'>Breastcancer.org: Mastectomy</a> </li></ul>
See more
31

NEAREST SITE: 2314 miles
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem,NC

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT03987555

Studying the Amount of Chemotherapy in the Blood in People with Breast Cancer

Pilot Feasibility Study of Paclitaxel Therapeutic Drug Monitoring in Cancer Patients Scientific Title

Purpose
To study the ability of researchers to measure the amount of paclitaxel (Taxol®) in blood and study the effect of paclitaxel (Taxol®) on neuropathy.
Who is this for?
People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive treatment with paclitaxel (Taxol®) at Wake Forest Comprehensive Cancer Center.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood draws</li> <li class="seamTextUnorderedListItem">Surveys about neuropathy</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for trial schedule</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®) is a chemotherapy drug.</li> <li class="seamTextUnorderedListItem">Neuropathy is pain from nerve damage.</li> <li class="seamTextUnorderedListItem">Nerve damage is one of the most common and severe side effects of paclitaxel (Taxol®).</li> <li class="seamTextUnorderedListItem">The ability to consistently measure paclitaxel (Taxol®) in the blood may allow doctors to control the dose of paclitaxel, so that enough chemotherapy is given to kill the cancer, but the side effect of nerve damage is reduced.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03987555' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://breastcancernow.org/information-support/facing-breast-cancer/going-through-treatment-breast-cancer/chemotherapy/paclitaxel-taxol' target='_blank'>Breast Cancer Now: Paclitaxel (Taxol®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/side_effects/neuropathy' target='_blank'>Breastcancer.org: Neuropathy</a> </li></ul>
See more
32

NEAREST SITE: 2314 miles
Wake Forest University Health Sciences
Winston-Salem,NC

VISITS: 1 visit

PHASE: NA

NCT ID: NCT03529565

A Blood Test to Study Bone Pain Related to Breast Cancer that has Spread to the Bones (Bone Metastases)

The Role of Histamine in Breast Cancer Bone Pain Scientific Title

Purpose
To study how certain blood markers relate to bone pain in breast cancer that has spread to the bone.
Who is this for?
People with metastatic (stage IV) breast cancer that has spread to the bone (bone metastases).    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood draw, at least one time</li> <li class="seamTextUnorderedListItem">Questionnaires </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for trial schedule</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cancer that has spread to the bone is called bone metastases. </li> <li class="seamTextUnorderedListItem">This trial is studying certain blood markers to see how they relate to bone pain.</li> <li class="seamTextUnorderedListItem">The markers being studied include histamines. </li> <li class="seamTextUnorderedListItem">Histamines are a biological signal that trigger your immune system.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03529565' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/diagnosing-treating-bone-metastases/' target='_blank'>Metastatic Trial Talk: Diagnosing & Treatment of Bone Metastases</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2992892/#:~:text=Further%20studies%20support%20the%20role,the%20onset%20of%20malignant%20transformation.' target='_blank'>Journal Article: Histamine Receptors and Cancer</a> </li></ul>
See more
33

NEAREST SITE: 2352 miles
University of Rochester Medical Center
Rochester,NY

VISITS: At least 8 visits

PHASE: NA

NCT ID: NCT04230941

MAAT-G Workshops and Workbook to Improve Cognition for People Ages 65+ With Breast Cancer After Completing Treatment

Mitigating Cancer-Related Cognitive Impairment in Older Adults With Breast Cancer Receiving Chemotherapy: Memory and Attention Adaptation Training-Geriatrics (MAAT-G) Phase I Scientific Title

Purpose
To study if the MAAT-G intervention can improve or maintain cognition for older adults after completing breast cancer treatment.
Who is this for?
People ages 65 or older with stage I, stage II, or stage III breast cancer who have completed standard treatment with chemotherapy and have mild cognitive problems.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MAAT-G intervention, 8 workshops and workbook</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for trial schedule</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Memory and Attention Adaptation Training (MAAT) is a cognitive-behavioral therapy (CBT)-based intervention for cancer-related cognitive problems.</li> <li class="seamTextUnorderedListItem">MAAT is a series of workshops delivered by a psychologist via video-conferencing, supplemented by a workbook, which provides instruction and practice with behavioral coping skills, stress management techniques, and other support strategies. </li> <li class="seamTextUnorderedListItem">MAAT is used for younger cancer survivors, but needs to be adapted for older adults to address their unique needs. </li> <li class="seamTextUnorderedListItem">Memory and Attention Adaptation Training-Geriatrics (MAAT-G) is MAAT for people over the age of 65.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04230941' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/20100913' target='_blank'>Breastcancer.org: Older Women More Likely to Have Chemo-Related Cognitive Problems</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/podcast/chemobrain-update' target='_blank'>Breastcancer.org (Podcast): Chemo Brain Update: Cancer-Related Cognitive Decline</a> </li></ul>
See more
34

NEAREST SITE: 2352 miles
University of Rochester
Rochester,NY

VISITS: 5 visits over 3-5 months

PHASE: NA

NCT ID: NCT03137095

Memory Problems During Chemotherapy in Patients with Stage I-III Breast Cancer

Longitudinal Pilot Mechanistic Study of the Effects of Chemotherapy on Cognitive Function in Breast Cancer Patients and Non-Cancer Control Participants Scientific Title

Purpose
To see if and how your cognitive functioning skills, like memory and concentration, change as you receive chemotherapy.
Who is this for?
Women who have been recently diagnosed with stage I, stage II, or stage III breast cancer who are planning to receive chemotherapy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will undergo the following over 3-5 months: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">3 computerized and paper-based cognitive tests during chemotherapy and 1 month after completion of chemotherapy</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers will give you cognitive tests during your chemotherapy treatment and one month after you have completed treatment.</li> </ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03137095' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
35

NEAREST SITE: 2353 miles
University of Florida CTSI Clinical Research Center
Gainesville,FL

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05473026

Gratitude Journaling and Goal Setting for Black Women with Breast Cancer and Breast Cancer Survivors

A Pilot Feasibility Study of a Gratitude Journaling Intervention to Enhance Well-being and Exercise Readiness in Older African American Female Breast Cancer Survivors Scientific Title

Purpose
To study the ability of gratitude journaling and goal setting to promote exercise and well-being.
Who is this for?
Black women with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who have received chemotherapy after surgery.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Gratitude journaling, daily for 2 months</li> <li class="seamTextUnorderedListItem">Goal setting, daily for 2 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">General journaling, daily for 2 months</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will receive a journal (paperback or electronic) and a daily journaling prompt depending on your group assignment.</li> <li class="seamTextUnorderedListItem">Goal setting will be based on the American Cancer Society's Nutrition, Physical Activity, and Cancer toolkit.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05473026' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/cancerwise/cultivating-gratitude-and-hope.h00-158905389.html' target='_blank'>MD Anderson Cancer Center: Gratitude During Cancer Treatment</a> </li><li class='seamTextUnorderedListItem'><a href='https://copingmag.com/gratitude-for-cancer-survivors/#:~:text=For%20cancer%20survivors%2C%20practicing%20gratitude,constantly%20about%20their%20cancer%20returning.' target='_blank'>Coping Magazine: Gratitude for Cancer Survivors</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/healthy/eat-healthy-get-active/acs-guidelines-nutrition-physical-activity-cancer-prevention/guidelines.html' target='_blank'>American Cancer Society: Guideline for Diet and Physical Activity</a> </li></ul>
See more
36

NEAREST SITE: 2354 miles
University of Florida
Gainesville,FL

VISITS: Coincides with routine care and surgery

PHASE: NA

NCT ID: NCT00811148

University of Florida Brain Tumor Tissue Bank

Establishment of a UF Brain Tumor Tissue Bank: Florida Center for Brain Tumor Research Scientific Title

Purpose
To collect and store brain tumor tissue samples for brain tumor research.
Who is this for?
People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) and are planning to receive brain surgery at the Florida Center for Brain Tumor Research.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tumor samples (during surgery)</li> <li class="seamTextUnorderedListItem">Blood samples</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The samples will become part of the University of Florida Brain Tumor Tissue Bank/Florida Center for Brain Tumor Research. </li> <li class="seamTextUnorderedListItem">The mission of the Florida Center for Brain Tumor Research is to discover cures and treatments for brain tumors.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT00811148' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>
See more
37

NEAREST SITE: 2383 miles
Mayo Clinic in Florida
Jacksonville,FL

VISITS: At least 3 visits

PHASE: NA

NCT ID: NCT04517838

Registry to Study Immune Response to Anti-HER2 Targeted Therapy for Stage I-IV HER2+ Breast Cancer

Immune Response to Anti-HER2 Therapies Scientific Title

Purpose
To study the relationship between immune cell response and treatment with anti-HER2 targeted therapy.
Who is this for?
Women with stage I, stage II, stage III, or stage IV (metastatic) HER2 positive (HER2+) breast cancer who are planning to begin treatment with anti-HER2 targeted therapy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples, 3 times within 4 months, 1 time at disease recurrence or progression</li> <li class="seamTextUnorderedListItem">Tumor samples</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The tumor samples will be used for genetic testing.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04517838' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy/what-are-anti-her2-therapies' target='_blank'>Breastcancer.org: Anti-HER2 Targeted Therapy</a> </li></ul>
See more
38

NEAREST SITE: 2385 miles
Duke University Medical Center
Durham,NC

VISITS: Number of visits unavailable, over 2 years

PHASE: II

NCT ID: NCT04352777

The Effects of Anti-Estrogen Therapy and Abemaciclib on the Tumor Microenvironment in Women with Advanced ER+, HER2- Breast Cancer

Evaluation of the Effects of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer Scientific Title

Purpose
To study the effects anti-estrogen therapy and the CDK 4/6 inhibitor abemaciclib (Verzenio®) have on the microenvironment around the tumor (the tissue around the tumor).
Who is this for?
Women with locally advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who are about to start standard of care anti-estrogen therapy with the CDK 4/6 inhibitor abemaciclib (Verzenio®).    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care anti-estrogen therapy and the CDK 4/6 inhibitor abemaciclib (Verzenio®)</li> <li class="seamTextUnorderedListItem">2 biopsies</li> <li class="seamTextUnorderedListItem">Blood tests</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The microenvironment is the tissue surrounding a tumor. </li> <li class="seamTextUnorderedListItem">This trial will be looking at changes in the immune system in the tumor's microenvironment. </li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®) is a CDK 4/6 inhibitor that is commonly used to treat metastatic, hormone positive (ER+ and/or PR+) breast cancer. </li> <li class="seamTextUnorderedListItem">The anti-estrogen therapies used in this trial are fulvestrant (Faslodex®) and letrozole (Femara®). Both are commonly used to treat advanced, hormone receptor positive (ER+ and/or PR+) breast cancer.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a type of hormone therapy called a selective estrogen receptor degrader (SERD).</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04352777' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Abemaciclib' target='_blank'>Wikipedia: Abemaciclib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/types/recur_metast/treat_metast/options/hormonal' target='_blank'>Breastcancer.org: Hormonal Therapy to Treat Metastatic Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://pubmed.ncbi.nlm.nih.gov/26330355/' target='_blank'>Journal Article: Role of the Tumor Microenvironment in Breast Cancer</a> </li></ul>
See more
39

NEAREST SITE: 2385 miles
Duke Cancer Center
Durham,NC

VISITS: Coincides with routine care

PHASE: NA

NCT ID: NCT05480644

Studying Biomarkers, Immune Cells, and ctDNA in People with Brain Metastasis

Circulating Biomarkers Repository in Adults Diagnosed With Primary and Metastatic Brain Tumors Scientific Title

Purpose
To study biomarkers, immune cells, and circulating tumor (ctDNA) in blood samples after radiation.
Who is this for?
People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are receiving radiation at Duke Cancer Center.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood tests will be used for genetic testing to indicate the presence of biomarkers, immune cells, and circulating tumor (ctDNA).</li> <li class="seamTextUnorderedListItem">Circulating tumor DNA (ctDNA) are small pieces of cancer cell DNA in the bloodstream.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05480644' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>
See more
40

NEAREST SITE: 2406 miles
Terri Eubanks
Chapel Hill,NC

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05574478

Interviews to Assess Prognosis of People with Metastatic Breast Cancer

Evaluation of the Acceptability, Appropriateness, Feasibility and Utility of a Metastatic Breast Cancer-Specific Prognostic Tool Among Patients With Metastatic Breast Cancer and Their Caregivers Scientific Title

Purpose
To develop a tool to help doctors assess the prognosis of people with metastatic breast cancer.
Who is this for?
People with stage IV (metastatic) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will complete the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Interview, 1 time</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The interview will be conducted over the phone or secure videoconferencing.</li> <li class="seamTextUnorderedListItem">Rather than simply developing a tool that may not be adopted into practice, this trial aims to ensure successful implementation of an evidence-based tool into the routine care of people with metastatic breast cancer. Doing so will serve as an important step towards ensuring high-quality, patient-centered end-of-life care.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05574478' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/types/metastatic/end-of-life-issues' target='_blank'>Breastcancer.org: Planning Ahead for End of Life</a> </li></ul>
See more
41

NEAREST SITE: 2432 miles
National Institutes of Health Clinical Center
Bethesda,MD

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT02851706

Registry of People With Brain Metastasis

Evaluation of the Natural History of and Specimen Banking for Patients With Tumors of the Central Nervous System Scientific Title

Purpose
To study brain tumors and discover areas for further brain tumor research.
Who is this for?
People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis).    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Physical and neurological exams</li> <li class="seamTextUnorderedListItem">Medical history</li> <li class="seamTextUnorderedListItem">Blood tests</li> <li class="seamTextUnorderedListItem">Brain tumor survey</li> <li class="seamTextUnorderedListItem">Survey about your well-being and if you have signs of anxiety and depression</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Your doctor will discuss your test results with you to recommend treatment options.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02851706' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>
See more
42

NEAREST SITE: 2453 miles
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore,MD

VISITS: Please contact research site

PHASE: NA

NCT ID: NCT01937039

Johns Hopkins Breast Cancer Program Tissue Bank

Johns Hopkins Breast Cancer Program Longitudinal Repository Scientific Title

Purpose
To study what causes breast cancer and how to treat breast cancer.
Who is this for?
People being seen at Johns Hopkins for breast cancer treatment, or for any screening or diagnostic breast procedures.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will provide blood, urine, and tissue samples periodically over time (up to 20 years).</p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The Breast Cancer Program at Johns Hopkins, in Baltimore, Maryland, has started a Longitudinal Repository-also known as a tissue bank.</li> <li class="seamTextUnorderedListItem">The Repository will store blood, breast tissue and urine samples donated periodically for up to 20 years by people with breast cancer or benign breast disease; as well as people never diagnosed with breast cancer. </li> <li class="seamTextUnorderedListItem">The Repository will provide blood, tissue, and urine samples to breast cancer researchers.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01937039' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
43

NEAREST SITE: 2539 miles
Memorial Sloan Kettering Basking Ridge
Basking Ridge,NJ

VISITS: 4 visits over 1 year, then annual visits for 5 years

PHASE: NA

NCT ID: NCT01788839

Sexual and Reproductive Health of Women Treated for Breast Cancer

Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma Scientific Title

Purpose
To study how to identify which women are most likely to develop early menopause or sexual problems during cancer therapy, or have difficulty getting pregnant after cancer treatment.
Who is this for?
Women, 50 or younger, diagnosed with DCIS or stage I, stage II, or stage III breast cancer who are within one month of starting treatment.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sexual and Reproductive Health survey, 9 times over 5 years</li> <li class="seamTextUnorderedListItem">If you receive chemotherapy, optional blood draw, 3 times over 2 years</li> <li class="seamTextUnorderedListItem">If you are premenopausal and only receive tamoxifen, blood draws, 12 times over 2 years and transvaginal ultrasound, 2 times, at baseline and 6 months</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cancer and its treatment may affect sexual and reproductive health.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling women with other types of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01788839' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.mskcc.org/cancer-care/trial/12-249' target='_blank'>Memorial Sloan Kettering Cancer Center: Study Website</a> </li></ul>
See more
44

NEAREST SITE: 2569 miles
Brooklyn Methodist Hospital - NewYork Presbyterian
New York,NY

VISITS: Coincides with routine care and surgery

PHASE: NA

NCT ID: NCT05134779

Tumor Registry for Triple Negative Breast Cancer

De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You Scientific Title

Purpose
To create a large registry of tumor samples, called a biobank or tumor bank, to help researchers study triple negative breast cancer and discover new treatments.
Who is this for?
People with stage I, stage II, stage III, or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will provide the following at different timepoints during your treatment: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood samples</li> <li class="seamTextUnorderedListItem">Tumor samples (during surgery)</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood and tumor samples will be taken at the following timepoints (if relevant): diagnosis, surgery, recurrence, and/or metastasis.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05134779' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/types/triple-negative' target='_blank'>Breastcancer.org: Triple-Negative Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://seer.cancer.gov/registries/cancer_registry/index.html' target='_blank'>National Cancer Institute: What is a Cancer Registry?</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org/' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li></ul>
See more
45

NEAREST SITE: 2572 miles
Kings County Hopsital Center
Brooklyn,NY

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT04751435

Developing Genetic Testing Education for Diverse Groups of People with Breast Cancer

Prospective Trial of a Linguistically and Culturally Appropriate Mainstreaming Model for Hereditary Cancer Multigene Panel Testing Among Diverse Cancer Patients Scientific Title

Purpose
To develop educational materials about genetic testing for people that speak different languages and have diverse cultural backgrounds.
Who is this for?
People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Interview</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Genetic testing is a type of test that detects changes to the genes, the DNA instructions that are passed on from the mother and father.</li> <li class="seamTextUnorderedListItem">The results of a genetic test can confirm whether the participant has a genetic disorder, which is a disease caused in whole or in part by changes to the genes. Genetic testing can also help determine a person's chance of getting or passing on a genetic disorder.</li> <li class="seamTextUnorderedListItem">The information gathered from your interview will be used to develop educational materials about genetic testing.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04751435' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cdc.gov/genomics/gtesting/genetic_testing.htm' target='_blank'>Centers for Disease Control and Prevention: Genetic Testing</a> </li></ul>
See more
46

NEAREST SITE: 2573 miles
Cleveland Clinic Florida
Weston,FL

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05598879

Registry to Study Cardiovascular Health and Risk Factors in People with Breast Cancer

Global Cardio Oncology Registry Scientific Title

Purpose
To collect information on the diagnosis and treatment of cardiovascular health and risk factors in people with breast cancer.
Who is this for?
People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Collection of health information</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Some breast cancer treatments can cause or increase the risk of heart problems, which is called cardiotoxicity.</li> <li class="seamTextUnorderedListItem">This study uses clinical, laboratory, imaging, demographic, and socioeconomic information to study cardiovascular (heart and blood vessels) health and risk factors before, during, or after cancer treatment.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05598879' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.heart.org/en/news/2020/02/19/what-women-need-to-know-about-breast-cancer-and-heart-disease' target='_blank'>American Heart Association: Breast Cancer and Heart Disease</a> </li></ul>
See more
47

NEAREST SITE: 2684 miles
Lifespan Cancer Institute
Providence,RI

VISITS: n/a

PHASE: NA

NCT ID: NCT03818087

Elevate! Improving Outcomes for Older Patients With Breast Cancer

Elevate! : Improving Outcomes for Older Patients With Breast Cancer:a Longitudinal Cohort and Patient Engagement Study Scientific Title

Purpose
To study the treatments, side effects, and outcomes of people 70 or older treated for breast cancer.
Who is this for?
People age 70 or older with stage I, stage II, or stage III breast cancer..    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> Your health information will be tracked for 5 years.</p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study will collect data on breast cancer patients age 70 and older to learn more about the specific treatments, side effects, and outcomes of this group of patients.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03818087' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.bcrf.org/blog/breast-cancer-elderly-how-bcrf-researchers-are-treating-growing-patient-population' target='_blank'>Breast Cancer Research Foundation: Breast Cancer in the Elderly: How BCRF Researchers are Treating this Growing Patient Population</a> </li><li class='seamTextUnorderedListItem'><a href='https://theoncologist.alphamedpress.org/content/15/suppl_5/57.full' target='_blank'>The Oncologist: Coming of Age: Breast Cancer in Seniors</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/web-exclusives/treatment-considerations-in-older-patients-with-breast-cancer' target='_blank'>Oncolive: Treatment Considerations in Older Patients With Breast Cancer</a> </li></ul>
See more
48

No Travel Required

VISITS: No visits required

PHASE: NA

NCT ID: NCT05179824

A Registry of Cancer Patient Data to Further Research and Improve Cancer Care

Tempus Priority Study: An Observational Study of Patients Who Have Received Comprehensive Genomic Profiling Scientific Title

Purpose
To create a data registry of cancer patient information to be used for future research to improve cancer treatment.
Who is this for?
People with stage I, stage II, or stage III breast cancer who have received or will receive genomic testing of their tumor.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> Your genomic test results, clinical health information, and long-term outcome health information will be collected by your doctor and submitted to the Tempus Labs patient data registry.</p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Genomic testing is done by testing your tumor sample for mutations. </li> <li class="seamTextUnorderedListItem">Tempus is a company that collects patients' health and cancer information and makes that information accessible and useful for patients, physicians, and researchers.</li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other types of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05179824' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.tempus.com/news/pr/tempus-launches-prospective-priority-research-study-and-increases-support-for-oncology-research-initiatives-despite-pandemic-challenges/' target='_blank'>Tempus Labs Press Release</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/genetic-vs-genomic-testing/' target='_blank'>Metastatic Trial Talk: Genetic vs. Genomic Testing</a> </li></ul>
See more
49

No Travel Required

VISITS: Saliva sample and questionnaires

PHASE: NA

NCT ID: NCT02253251

A Study of the Inherited KRAS-Variant Mutation and Breast Cancer Risk

Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment Scientific Title

Purpose
To analyze the association between the KRAS-variant mutation and cancer risk.
Who is this for?
People with stage I, stage II, stage III and stage IV breast cancer    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> All participants will provide a saliva sample and answer questionnaires periodically over 10 years. Participants will be able to get their KRAS-variant test results after submitting their sample, at a discounted cost ($295). </p> <p class="seamTextPara"> Click here for the <a href="http://mirakind.org/study-eligibility-questionnaire/">Eligibility Survey</a></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">An inherited genetic mutation, a KRAS-variant, may increase a person's risk of developing breast or other types of cancer. </li> <li class="seamTextUnorderedListItem">This study will follow participants for 10 years. </li> <li class="seamTextUnorderedListItem">The researchers will also look at the effect that different lifestyle factors have on cancer risk. </li> <li class="seamTextUnorderedListItem">All participants will have a saliva sample tested for the KRAS-variant. </li> <li class="seamTextUnorderedListItem">To be eligible, participants must have a personal or family history of breast cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02253251' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://miradx.com/test/kras-variant/' target='_blank'>MiraKind Research Company: KRAS-Variant</a> </li><li class='seamTextUnorderedListItem'><a href='http://mirakind.org/study-eligibility-questionnaire/' target='_blank'>Research Company: Eligibility Survey</a> </li></ul>
See more
50

No Travel Required

VISITS: No visits required

PHASE: NA

NCT ID: NCT04028479

Registry to Improve Diagnosis and Treatment of Breast Cancer

The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT) Scientific Title

Purpose
To create a registry of diagnosis, testing, biomarker, treatment, and patient-reported outcomes data to improve cancer diagnosis and treatment.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Consent for data collection</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04028479' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://taprootco.com/root/' target='_blank'>Taproot Health: Trial Information Page</a> </li></ul>
See more
51

No Travel Required

VISITS: No visits required

PHASE: NA

NCT ID: NCT05612100

Studying Alopecia During Hormone Therapy in Women with Breast Cancer

Endocrine Therapy-Induced Alopecia Natural History Evaluation Among Female Breast Cancer Survivors Scientific Title

Purpose
To study the incidence, timing, duration, and severity of alopecia (hair loss) during hormone therapy.
Who is this for?
Women with stage I, stage II, or stage III hormone receptor positive (ER+ and/or PR+) breast cancer who are receiving or planning to receive hormone therapy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires, every 3 months for 2 years</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">While alopecia (hair loss) is a well-known side effect of many chemotherapy drugs, it has also been reported by women undergoing hormone therapy.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05612100' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment-side-effects/hair-loss' target='_blank'>Breastcancer.org: Alopecia/Hair Loss</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy' target='_blank'>Breastcancer.org: Hormone Therapy</a> </li></ul>
See more
52

No Travel Required

VISITS: No visits required

PHASE: NA

NCT ID: NCT05483283

Empowerment and Navigation Sessions for Latina Women Ages 30+ with Breast Cancer or a Family History of Breast/Ovarian Cancer

Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care Scientific Title

Purpose
To compare the impact of empowerment and navigation sessions with standard of care sessions on whether Latina women decide to receive genetic testing and/or genetic counseling.
Who is this for?
Latina women ages 30+ with stage I, stage II, stage III, or stage IV (metastatic) breast cancer or with a family history of breast or ovarian cancer. You must have one social determinant of health risk factor, such as: perceived financial struggles, transportation difficulties, exposure to violence, housing challenges, social isolation/challenges. You must not have received genetic testing or genetic counseling.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Empowerment and navigation sessions, by phone, 3 times within 3 weeks</li> <li class="seamTextUnorderedListItem">Personalized educational materials</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard of care sessions, by phone, 3 times within 3 weeks</li> <li class="seamTextUnorderedListItem">Personalized educational materials</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Empowerment and navigation sessions will discuss social determinants of heath, genetic risk factors, individual behavior change action plans, breast cancer screening, and diet and physical activity for breast cancer prevention.</li> <li class="seamTextUnorderedListItem">Standard of care sessions will discuss social determinants of heath, genetic risk factors, individual behavior change action plans, how to share breast cancer information, and testimonials and include role playing activities and group discussions.</li> <li class="seamTextUnorderedListItem">You can receive up to $100 for participation.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05483283' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-prevention-and-early-detection-facts-and-figures/making-the-case-for-health-equity.pdf' target='_blank'>American Cancer Society: Health Equity and Social Determinants of Health</a> </li><li class='seamTextUnorderedListItem'><a href='https://health.gov/healthypeople/priority-areas/social-determinants-health' target='_blank'>US Department of Health and Human Services: Social Determinants of Health</a> </li></ul>
See more
53

No Travel Required

VISITS: No visits required

PHASE: III

NCT ID: NCT05703178

Web-Based Coping Skills Training to Decrease Pain from Hormone Therapy

Web-based Pain Coping Skills Training to Improve Pain and Poor Adherence Caused by Aromatase Inhibitor-Associated Arthralgia In Breast Cancer Survivors (SKIP-Arthralgia): A Randomized Controlled Trial Scientific Title

Purpose
To study if an online pain coping skills training program reduces the severity and effects of pain from treatment with aromatase inhibitors.
Who is this for?
Postmenopausal women with stage I, stage II, or stage III hormone receptor positive (ER+ and/or PR+) breast cancer who have completed treatment. You must be taking an aromatase inhibitor and experience pain in your joints, bones, and/or muscles.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Online pain coping skills training program, weekly for 2-3 months</li> <li class="seamTextUnorderedListItem">Educational booklet about aromatase inhibitors and side effects</li> <li class="seamTextUnorderedListItem">Electronic pill bottle to track use of aromatase inhibitor medication</li> <li class="seamTextUnorderedListItem">Continue usual care</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Educational booklet about aromatase inhibitors and side effects</li> <li class="seamTextUnorderedListItem">Electronic pill bottle to track use of aromatase inhibitor medication</li> <li class="seamTextUnorderedListItem">Continue usual care</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional Procedures</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Questionnaires, 4 times within 9-10 months</li> <li class="seamTextUnorderedListItem">Virtual visits, 3 times within 1 month</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Aromatase inhibitors are a type of hormone therapy that block some production of estrogen that helps cancer grow. Approved aromatase inhibitors include anastrozole (Arimidex®), letrozole (Femara®), and exemestane (Aromasin®).</li> <li class="seamTextUnorderedListItem">Arthralgia is pain in the joints, bones, and/or muscles and is a common side effect of aromatase inhibitors.</li> <li class="seamTextUnorderedListItem">The online pain coping skills training is an interactive, web-based program that teaches cognitive and behavioral skills to reduce pain and pain-related interference with daily activities. The program includes 8 sessions that are 35-45 minutes each. You will complete about 1 session per week.</li> <li class="seamTextUnorderedListItem">If you do not have a device capable of accessing the program, you will be loaned a tablet computer for the study.</li> <li class="seamTextUnorderedListItem">Benefits of the online pain coping skills training may include reduced severity of pain, improvements in quality of life, and improved adherence to aromatase inhibitor medication. The training may also increase your confidence in managing your pain and reduce unhelpful thinking patterns about pain.</li> <li class="seamTextUnorderedListItem">The educational booklet contains information about aromatase inhibitors, side effects including arthralgia, methods for managing arthralgia, and tips for talking with doctors about arthralgia and other side effects.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05703178' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.scholars.northwestern.edu/en/projects/web-based-pain-coping-skills-training-to-improve-pain-and-poor-ad' target='_blank'>Northwestern University: Pain Coping Skills Training</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal-therapy/aromatase-inhibitors' target='_blank'>Breastcancer.org: Aromatase Inhibitors</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.komen.org/breast-cancer/treatment/type/hormone-therapy/aromatase-inhibitors/side-effects/' target='_blank'>Susan G Komen: Side Effects of Aromatase Inhibitors</a> </li></ul>
See more
54

No Travel Required

VISITS: No travel required

PHASE: NA

NCT ID: NCT05730010

Impact of ctDNA Information on Decision Making After Treatment

Discerning the Impact of ctDNA Detection on Patient Decision Making in Early Stage Breast Cancer: a Conjoint Analysis Scientific Title

Purpose
To study how circulating tumor DNA (ctDNA) information and genomic information affect how people make treatment decisions and if people at high risk for recurrence prioritize benefit over toxicity when considering treatment options.
Who is this for?
People with stage I, stage II, or stage III triple negative (ER-, PR-, HER2-) breast cancer who completed chemotherapy between 6 months and 10 years ago.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will complete the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Online survey, 1 time</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Circulating tumor DNA (ctDNA) are small bits of cancer cell DNA that specific tests can find in the bloodstream. The presence of ctDNA may indicate the presence of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05730010' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancernetwork.com/view/identifying-use-of-ctdna-across-tumor-types' target='_blank'>Cancer Network: ctDNA in Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://medlineplus.gov/genetics/understanding/testing/circulatingtumordna/' target='_blank'>MedLine Plus: What is ctDNA?</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/view/practical-advice-on-the-use-of-ctdna-testing-in-breast-cancer' target='_blank'>OncLive: ctDNA Testing in Breast Cancer</a> </li></ul>
See more
55

No Travel Required

VISITS: No visits required

PHASE: NA

NCT ID: NCT05587972

Remote Symptom Monitoring Registry for People with Breast Cancer

Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring Scientific Title

Purpose
To collect information about your symptoms and treatment experience.
Who is this for?
People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will complete the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Carevive surveys, weekly for at least 3 months</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You may choose to continue the weekly surveys as long as you are receiving treatment.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05587972' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.carevive.com/prompt/' target='_blank'>Carevive: Remote Symptom Monitoring</a> </li></ul>
See more
56

No Travel Required

VISITS: Online surveys

PHASE: NA

NCT ID: NCT02333604

CSC Online Survey: The Cancer Experience Registry

Cancer Experience Registry: An Online Initiative to Understand the Experiences of Those Impacted by a Cancer Diagnosis (CER) Scientific Title

Purpose
To learn more about the emotional and social experiences and needs of people affected by cancer.
Who is this for?
People diagnosed with DCIS, stage I, stage II, stage III, or metastatic (stage IV) breast cancer and people who provide care to individuals diagnosed with cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> Participation in this study involves the completion of an online questionnaire. The questionnaire may be accessed at the following link: </p> <a href="http://www.cancersupportcommunity.org/MainMenu/ResearchTraining/Cancer-Experience-Registry.html" target="_blank">www.cancerexperienceregistry.org</a>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The researchers hope to use this information to improve the educational materials and the overall quality of care that cancer patients receive. </li> <li class="seamTextUnorderedListItem">This study is also enrolling people diagnosed with other types of cancer. </li> <li class="seamTextUnorderedListItem">The data collected from this study can be found <a href="https://www.cancersupportcommunity.org/RegistryIndexReport2017" target="_blank">here.</a></li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02333604' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerexperienceregistry.org/' target='_blank'>Cancer Support Community Study Website: Cancer Experience Registry</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancersupportcommunity.org/RegistryIndexReport2017' target='_blank'>Cancer Support Community: Cancer Experience Registry Index Report 2017</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.youtube.com/watch?v=SyyUYqyNaCc' target='_blank'>Cancer Support Community YouTube Channel: What is the Cancer Experience Registry?</a> </li></ul>
See more
57

No Travel Required

VISITS: No visits required

PHASE: NA

NCT ID: NCT03452774

Using Artificial Intelligence to Match Patients to Clinical Trials (SYNERGY-AI)

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry Scientific Title

Purpose
To study if a computer that has been taught how to match people to clinical trials (artificial intelligence) can help increase enrollment in clinical trials.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer who have already decided to enroll in a clinical trial.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A clinical trial matching report based on your medical records that you can review with your doctor.</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This trial will use artificial intelligence and virtual tumor boards to help match people to clinical trials.</li> <li class="seamTextUnorderedListItem">The researchers will also create a registry to study the medical and financial effects of this program. </li> <li class="seamTextUnorderedListItem">This is an international trial that is also enrolling people with other types of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03452774' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://massivebio.com/' target='_blank'>Massive Bio Study Information Page</a> </li></ul>
See more
58

No Travel Required

VISITS: Mobile or online surveys

PHASE: NA

NCT ID: NCT00000003

MBC Connect Patient Registry: Sharing MBC History, Experiences, and Quality of Life

MBC Connect -- Patient Powered. Research Driven Scientific Title

Purpose
To collect information about the experiences of people with metastatic breast cancer for researchers and clinicians and to provide personalized information to each participant.
Who is this for?
People with metastatic (stage IV) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will be asked to fill out surveys about your breast cancer diagnosis, treatment history and quality of life.</li> <li class="seamTextUnorderedListItem">Based on information you enter, you will get personalized insights and alerts with MBC news, events, and clinical trial opportunities.</li> </ul> <p class="seamTextPara"> To join the registry, click here: <a href="https://www.mbcconnect.org/" target="_blank">www.mbcconnect.org/</a><p></p></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MBC Connect is a free, web and mobile-friendly registry that collects information about the experiences of people with metastatic breast cancer. </li> <li class="seamTextUnorderedListItem">Joining the registry allows you to receive personalized information about MBC-related news, events, and clinical trial opportunities. </li> <li class="seamTextUnorderedListItem">Researchers and clinicians will be able to analyze information collected in the registry in research studies. </li> <li class="seamTextUnorderedListItem">MBC Connect is available in English and Spanish.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'><a href='https://www.mbcconnect.org/' target='_blank'>MBC Connect</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mbcalliance.org/' target='_blank'>Metastatic Breast Cancer Alliance</a> </li></ul>
See more
59

No Travel Required

VISITS: Online forms, questionnaires, saliva sample by mail

PHASE: NA

NCT ID: NCT00000002

MBC Project: Collecting Information About Metastatic Breast Cancer To Further Research

The Metastatic Breast Cancer Project Scientific Title

Purpose
To accelerate research in treating, curing and preventing metastatic breast cancer.
Who is this for?
People with metastatic (stage IV) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> Your participation will include the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Complete a simple online form about yourself and your cancer</li> <li class="seamTextUnorderedListItem">Fill out an online consent form that gives your permission for the researchers to obtain copies of your medical records and some of your stored tumor tissue</li> <li class="seamTextUnorderedListItem">Provide a saliva sample and send back via U.S. mail </li> </ul> <p class="seamTextPara"> To learn more and/or to participate, click here: <a href="https://www.mbcproject.org/" target="_blank">https://www.mbcproject.org/</a><p></p></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The goal of the Metastatic Breast Cancer Project is to accelerate research in treating, curing and preventing metastatic breast cancer. </li> <li class="seamTextUnorderedListItem">If you take part in the project, you will fill out questionnaires, provide a saliva sample, and share a piece of your stored tumor tissue and copies of your medical records with the researchers. </li> <li class="seamTextUnorderedListItem">The researchers believe analyzing this data will help them learn more about metastatic breast cancer and make more research advances. </li> <li class="seamTextUnorderedListItem">The MBC Project was created by a coalition of researchers and breast cancer advocacy organizations.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'><a href='https://www.mbcproject.org/' target='_blank'>The Metastatic Breast Cancer Project</a> </li></ul>
See more